Yogesh Sabnis
Yogesh Sabnis
UCB Biopharma
Verified email at
Cited by
Cited by
Developing irreversible inhibitors of the protein kinase cysteinome
Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray
Chemistry & biology 20 (2), 146-159, 2013
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database
PV Desai, A Patny, Y Sabnis, B Tekwani, J Gut, P Rosenthal, A Srivastava, ...
Journal of medicinal chemistry 47 (26), 6609-6615, 2004
Structure− activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies
MA Avery, M Alvim-Gaston, CR Rodrigues, EJ Barreiro, FE Cohen, ...
Journal of medicinal chemistry 45 (2), 292-303, 2002
Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3
R Rönn, YA Sabnis, T Gossas, E Ĺkerblom, U Helena Danielson, ...
Bioorganic & medicinal chemistry 14 (2), 544-559, 2006
Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1, 6, 7-trisubstituted dihydroisoquinolines and isoquinolines
S Batra, YA Sabnis, PJ Rosenthal, MA Avery
Bioorganic & medicinal chemistry 11 (10), 2293-2299, 2003
Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies
YA Sabnis, PV Desai, PJ Rosenthal, MA Avery
Protein Science 12 (3), 501-509, 2003
Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering
D Muthas, YA Sabnis, M Lundborg, A Karlén
Journal of Molecular Graphics and Modelling 26 (8), 1237-1251, 2008
Interaction of artemisinin and its related compounds with hydroxypropyl‐β‐cyclodextrin in solution state: Experimental and molecular‐modeling studies
AC Illapakurthy, YA Sabnis, BA Avery, MA Avery, CM Wyandt
Journal of pharmaceutical sciences 92 (3), 649-655, 2003
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target
DC Miller, G Lunn, P Jones, Y Sabnis, NL Davies, P Driscoll
MedChemComm 3 (4), 449-452, 2012
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors
P Örtqvist, SD Peterson, E Ĺkerblom, T Gossas, YA Sabnis, R Fransson, ...
Bioorganic & medicinal chemistry 15 (3), 1448-1474, 2007
Evaluation of a diverse set of potential P< sub> 1</sub> carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors
R Rönn, T Gossas, YA Sabnis, H Daoud, E Ĺkerblom, UH Danielson, ...
Bioorganic & medicinal chemistry 15 (12), 4057-4068, 2007
Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors
Y Sabnis, PJ Rosenthal, P Desai, MA Avery
Journal of Biomolecular Structure and Dynamics 19 (5), 765-774, 2002
Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of …
P Jones, RI Storer, YA Sabnis, FM Wakenhut, GA Whitlock, KS England, ...
Journal of medicinal chemistry 60 (2), 767-786, 2017
Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II
D Muthas, D Nöteberg, YA Sabnis, E Hamelink, L Vrang, B Samuelsson, ...
Bioorganic & medicinal chemistry 13 (18), 5371-5390, 2005
Pyrazolopyridines and pyrazolopyrimidines
JW Coe, CM Dehnhardt, P Jones, YA Sabnis, JW Strohbach, ...
US Patent 9,518,052, 2016
JW Coe, CM Dehnhardt, P Jones, SW Kortum, YA Sabnis, FM Wakenhut, ...
US Patent 8,575,336, 2013
A new structural theme in< i> C</i>< sub> 2</sub>-symmetric HIV-1 protease inhibitors:< i> ortho</i>-Substituted P1/P1′ side chains
J Wannberg, YA Sabnis, L Vrang, B Samuelsson, A Karlén, A Hallberg, ...
Bioorganic & medicinal chemistry 14 (15), 5303-5315, 2006
JW Coe, CM Dehnhardt, P Jones, SW Kortum, YA Sabnis, FM Wakenhut, ...
US Patent App. 14/041,387, 2013
The promise of AI for DILI prediction
A Vall, Y Sabnis, J Shi, R Class, S Hochreiter, G Klambauer
Frontiers in Artificial Intelligence 4, 638410, 2021
Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo [3.1. 0] hexane core. An example of a ‘magic methyl’giving a 35-fold improvement in binding
G Lunn, BJ Banks, R Crook, N Feeder, A Pettman, Y Sabnis
Bioorganic & medicinal chemistry letters 21 (15), 4608-4611, 2011
The system can't perform the operation now. Try again later.
Articles 1–20